Helocyte
  • Home
  • About Us
    • Management Team
    • Scientific Advisory Board
  • Pipeline
    • CMV
    • Triplex
    • ConVax
    • Publications
  • Business Development
  • Investors
    • Corporate Presentation
    • Press Releases
  • Contact Us

February 16,2023

Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

February 15,2023

Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex

December 16,2021

Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

October 28,2016

Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood

April 21,2016

HELOCYTE ANNOUNCES CORPORATE AND CLINICAL MILESTONES

April 02,2015

FORTRESS BIOTECH (f/k/a Coronado Biosciences) FORMS NEW SUBSIDIARY, HELOCYTE, INC. (f/k/a DiaVax Biosciences) TO DEVELOP NOVEL IMMUNOTHERAPIES FOR CYTOMEGALOVIRUS
  • © Copyright 2023 Helocyte, Inc.
  • Home
  • Contact Us
  • Privacy Policy
  • Disclaimer